Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Alnylam Pharmaceuticals 3Q EPS $1.15 >ALNY
Exxon, Lockheed, Northrop, Delta, Mirati, Alnylam, SolarEdge, and More Stock Market Movers
Alnylam Is Now 'One Of The Most Binary' Stories In Biotech. Why The FDA Rejected Its Heart Drug.
Alnylam Stock Is Dropping on Surprising FDA Rejection
Alnylam Ending Onpattro ATTR-CM Pursuit After FDA Rejection
Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer
Alnylam Pharmaceuticals Says FDA Panel Votes in Favor of Onpattro's sNDA
BridgeBio Launches 76% And Pulls Its Rival Higher On Bullish Heart Drug News
Karuna's Schizophrenia Data Are 'Best Case Scenario' for the Stock
The Bull Market in Biotech Is Still Going Strong
Alnylam Shares Soar as Drug Trial for Heart Disease Delivers Positive Results
Alnylam Stock Rockets 50% as Trial Results Raise Hope for a Blockbuster
Drugmakers Hope New Heart Drugs Boost Sales, Revive Market
New Patent Lawsuit Adds to Litigation Worries for Moderna Stock
Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough
First In-Vivo Gene Editing Data Look Good for Intellia
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.